3669
-
Biologics: Targets & Therapy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Biologics: Targets & Therapy
(405,151) Views
Editor in Chief Professor Doris Mangiaracina Benbrook
1177-5475
Preventative and therapeutic vaccination to combat an experimental autoimmune kidney diseaseArpad Z Barabas, Chad D Cole, Arpad D Barabas, Rene Lafreniere
Potential of adult neural stem cells for cellular therapy
Philippe Taupin
Role of basiliximab in the prevention of acute cellular rejection in adult to adult living-related liver transplantation: a single center experience || FREE PAPER ||
S Gruttadauria, L Mandalà , D Biondo, M Spampinato, V Lamonaca, et al
Editorial || FREE PAPER ||
Sanjay Awasthi
Trastuzumab in the management of early and advanced stage breast cancer
Rupert Bartsch, Catharina Wenzel, Guenther G Steger
Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)
Joseph M Geskey, Neal J Thomas, Gretchen L Brummel
Treatment of ankylosing spondylitis: focus on etanercept
Tracy Frech
First line targeted therapies in breast cancer: focus on bevacizumab || FREE PAPER ||
Amalia Milano, Gugliemo Nasti, Rosario Vincenzo Iaffaioli, Francesco Caponigro
Biological markers in the etiology of psoriasis: Targeted treatment options
Catia de Felice, Georgiana Clare Marulli, Marco Ardigò, Enzo Berardesca
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Journal Indexing
See where all the Dove Press journals are indexed
